ArticleAnnals of surgical oncology2026
Clinicopathological Features and Management of Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS).
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare hereditary gastric cancer syndrome linked to APC promoter IB variants and characterized by gastric polyposis. Its natural history and management are poorly defined. We sought to characterize the clinicopathological features of GAPPS and infer management guidelines. PATIENTS AND
methodsWe retrospectively analyzed individuals with GAPPS enrolled in a natural history study from January 2017 to September 2023. Demographics, pathogenic gene variants, endoscopic findings, and histopathology results were studied.
resultsOf 21 patients with GAPPS, 11 (52%) were male, and most were non-Hispanic white (71%). Median age at germline genetic testing was 44 years (range 12-75 years), and all individuals had a pathogenic variant in the APC promoter IB. Esophagogastroduodenoscopy (EGD) was performed in almost all patients (91%), with a median age of 37 years (range 12-75 years) at initial EGD. Gastric polyps carpeting the fundus and body with antral sparing were noted in all individuals. Gastric adenocarcinoma (n = 3), high-grade dysplasia (n = 7), low-grade dysplasia (n = 3), and benign fundic gland polyposis (n = 6) were demonstrated on endoscopic biopsies. Then, 43% (9/21) of patients underwent total gastrectomy (TG) at a median age of 44 years (range 15-63 years). Histopathology of final gastrectomy specimens demonstrated more advanced pathology compared with endoscopic biopsies in five of nine patients.
conclusionsGiven the challenge of effective endoscopic surveillance owing to extensive polyposis, and the risk of malignant transformation, prophylactic TG should be considered for patients with GAPPS. Longitudinal studies are needed to delineate lifetime cancer risk and clinical management guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.